Sign in Subscribe
Class action lawsuits

Sarepta Therapeutics, Inc. Faces Securities Lawsuit Over Alleged Misstatements and Consequences of ELEVIDYS Gene Therapy

Strategic Insights

— 1 min read

A class action securities lawsuit was filed against Sarepta Therapeutics, Inc., alleging that the company made false statements and concealed the safety risks associated with its ELEVIDYS prescription gene therapy for Duchenne. The lawsuit seeks to recover losses of shareholders who were adversely affected between June 22, 2023, and June 24, 2025. The complaint alleges that defendants failed to detect severe side effects in ELEVIDYS trial regimes and protocols, which led to the company halting recruitment and dosing in ELEVIDYS trials, attracting regulatory scrutiny, and increasing risk around the therapy's present and expanded approvals.

Key Takeaways:

  • The lawsuit alleges that Sarepta Therapeutics, Inc. made false statements and concealed the safety risks associated with ELEVIDYS.
  • The complaint alleges that ELEVIDYS trial regimes and protocols failed to detect severe side effects.
  • Sarepta Therapeutics, Inc. halted recruitment and dosing in ELEVIDYS trials, attracting regulatory scrutiny, and creating greater risk around the therapy's present and expanded approvals.
  • The lawsuit seeks to recover losses of shareholders who suffered between June 22, 2023, and June 24, 2025.
  • The complaint alleges that defendants lacked a reasonable basis for their positive statements about ELEVIDYS.
  • Levi & Korsinsky LLP, a nationally-recognized securities litigation firm, is representing investors in the lawsuit.

Statistics:

  • June 22, 2023, to June 24, 2025: relevant time frame for the lawsuit.
  • 70: number of employees at Levi & Korsinsky LLP.
  • 20 years: the number of years Levi & Korsinsky LLP has been in practice.
  • 7 years in a row: the number of years Levi & Korsinsky has ranked in the ISS Securities Class Action Services' Top 50 Report.
  • Hundreds of millions of dollars: the amount secured by Levi & Korsinsky LLP for aggrieved shareholders.

Sources:

  • Sarepta Therapeutics, Inc. (NASDAQ: SRPT)
  • Levi & Korsinsky LLP
  • Newsfile Corp.
  • ISS Securities Class Action Services' Top 50 Report
  • https://zlk.com/
  • https://www.newsfilecorp.com/release/261348

Read more